Baird raised the firm’s price target on Neurocrine to $157 from $152 and keeps an Outperform rating on the shares. The firm said it expecst a near-term regulatory filing following its positive pediatric CAH data to set up an approval encompassing adult and pediatric patients , followed by rapid incorporation by treating physicians and thinks this further derisks approval.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine Stock (NASDAQ:NBIX) Gains on Positive Pediatric Phase 3 Results
- Neurocrine’s crinecerfont meets primary and secondary endpoints in Phase 3 trial
- Neurocrine participates in a conference call with William Blair
- Neurocrine price target raised to $135 from $125 at Barclays
- Neurocrine presenting post hoc data analysis in congenital adrenal hyperplasia
